X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (160472) 160472
Book Review (34948) 34948
Publication (19710) 19710
Newsletter (1309) 1309
Newspaper Article (1124) 1124
Book Chapter (1064) 1064
Book / eBook (520) 520
Conference Proceeding (389) 389
Dissertation (162) 162
Magazine Article (54) 54
Reference (35) 35
Transcript (22) 22
Data Set (18) 18
Trade Publication Article (11) 11
Web Resource (8) 8
Government Document (5) 5
Paper (4) 4
Presentation (3) 3
Report (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (137805) 137805
animals (92710) 92710
humans (82310) 82310
male (44174) 44174
mice (43162) 43162
proteins (35537) 35537
female (29273) 29273
rats (28704) 28704
apoptosis (27021) 27021
oncology (25137) 25137
cell biology (23837) 23837
cancer (23584) 23584
kinases (22768) 22768
signal transduction (21668) 21668
research (20880) 20880
biochemistry & molecular biology (20700) 20700
expression (20560) 20560
pharmacology & pharmacy (19979) 19979
phosphorylation (19919) 19919
neurosciences (18797) 18797
gene expression (18514) 18514
rodents (18503) 18503
analysis (18005) 18005
activation (17117) 17117
inflammation (15620) 15620
physiological aspects (15347) 15347
article (15054) 15054
cell line, tumor (14901) 14901
health aspects (14750) 14750
research article (13897) 13897
signal transduction - drug effects (13873) 13873
oxidative stress (13515) 13515
medicine (12905) 12905
cells, cultured (12892) 12892
multidisciplinary sciences (12792) 12792
disease models, animal (12218) 12218
care and treatment (12147) 12147
rats, sprague-dawley (12028) 12028
physiology (12009) 12009
cells (11928) 11928
mice, inbred c57bl (11636) 11636
apoptosis - drug effects (11634) 11634
inhibition (10834) 10834
genetic aspects (10524) 10524
immunology (10176) 10176
science (9843) 9843
middle aged (9655) 9655
gene-expression (9631) 9631
medicine, research & experimental (9585) 9585
tumors (9568) 9568
dose-response relationship, drug (9473) 9473
in-vivo (9377) 9377
endocrinology & metabolism (9264) 9264
in-vitro (8920) 8920
biology (8587) 8587
mutation (8502) 8502
cytokines (8321) 8321
adult (8273) 8273
cell line (8043) 8043
studies (8031) 8031
chemotherapy (7918) 7918
nf-kappa-b (7879) 7879
brain (7876) 7876
cell proliferation - drug effects (7872) 7872
biochemistry (7713) 7713
aged (7683) 7683
protein kinases (7659) 7659
metabolism (7543) 7543
protein (7451) 7451
abridged index medicus (7426) 7426
development and progression (7003) 7003
blotting, western (6951) 6951
enzymes (6889) 6889
cell proliferation (6875) 6875
time factors (6847) 6847
antineoplastic agents - pharmacology (6821) 6821
rats, wistar (6766) 6766
cell cycle (6525) 6525
neurons (6507) 6507
growth (6301) 6301
immunohistochemistry (6278) 6278
activated protein-kinase (6270) 6270
medicine & public health (6260) 6260
medical research (6254) 6254
mice, knockout (6196) 6196
genes (6171) 6171
metastasis (6151) 6151
protein kinase inhibitors - pharmacology (6095) 6095
enzyme inhibitors - pharmacology (6068) 6068
antineoplastic agents - therapeutic use (6058) 6058
drug therapy (6033) 6033
diabetes (5949) 5949
neurology (5945) 5945
biomedicine (5736) 5736
angiogenesis (5718) 5718
review (5704) 5704
protein binding (5687) 5687
proto-oncogene proteins c-akt - metabolism (5668) 5668
pharmacology (5667) 5667
signal transduction - physiology (5626) 5626
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (362) 362
UofT at Mississauga - Stacks (36) 36
Collection Dvlpm't (Acquisitions) - Vendor file (30) 30
UTL at Downsview - May be requested (27) 27
Collection Dvlpm't (Acquisitions) - Closed Orders (18) 18
Online Resources - Online (15) 15
UofT at Scarborough - Stacks (15) 15
Chemistry (A D Allen) - Stacks (12) 12
Engineering & Comp. Sci. - Stacks (12) 12
Earth Sciences (Noranda) - Stacks (8) 8
Gerstein Science - Circulation Desk (3) 3
St. Michael's College (John M. Kelly) - 2nd Floor (3) 3
UofT at Scarborough - Withdrawn (3) 3
Physics - Stacks (2) 2
UofT at Mississauga - Reference (2) 2
Chemistry (A D Allen) - May be requested in 6-10 wks (1) 1
Collection Dvlpm't (Acquisitions) - Cancelled Order (1) 1
Engineering & Comp. Sci. - Reference (1) 1
Gerstein Science - Reference (1) 1
Law (Bora Laskin) - Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
UofT at Mississauga - Missing (1) 1
UofT at Scarborough - May be requested in 6-10 wks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (163552) 163552
Chinese (123) 123
Japanese (116) 116
German (108) 108
French (103) 103
Spanish (55) 55
Russian (30) 30
Hungarian (11) 11
Korean (10) 10
Polish (9) 9
Czech (8) 8
Danish (6) 6
Italian (5) 5
Swedish (4) 4
Dutch (3) 3
Norwegian (3) 3
Arabic (2) 2
Portuguese (2) 2
Turkish (2) 2
Ukrainian (2) 2
Hebrew (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Alcoholism: Clinical and Experimental Research, ISSN 0145-6008, 07/2016, Volume 40, Issue 7, pp. 1524 - 1530
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 18, pp. 1689 - 1699
AZD9291, an irreversible inhibitor of epidermal growth factor receptor, was associated with tumor responses in the majority of patients with advanced... 
MEDICINE, GENERAL & INTERNAL | GEFITINIB | PLACEBO | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | MUTATIONS | AFATINIB | IRREVERSIBLE EGFR | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aniline Compounds - administration & dosage | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Aniline Compounds - pharmacokinetics | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Patient outcomes | Tyrosine | Appetite | Inhibitor drugs | Epidermal growth factor receptors | Lung | Lung cancer | Diarrhea | Nausea | Drug resistance | Kinases | Patients | Epidermal growth factor | Pharmacokinetics | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 25 - 35
Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EXEMESTANE | ONCOLOGY | CELL-CYCLE | POSTMENOPAUSAL WOMEN | HER2 | PLUS | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Triazoles - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Molecular Targeted Therapy | North America | Nitriles - administration & dosage | Breast Neoplasms - enzymology | Time Factors | Postmenopause | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Republic of Korea | Aromatase Inhibitors - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Europe | Proportional Hazards Models | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Cyclin D1 - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | South Africa | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Care and treatment | Oncology, Experimental | Estrogen | Breast cancer | Research | Antineoplastic agents | Phosphotransferases | Cancer | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 22, pp. 2071 - 2082
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 3, pp. 207 - 215
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2010, Volume 363, Issue 18, pp. 1693 - 1703
A small group of patients with non–small-cell lung cancer have genetic lesions that activate anaplastic lymphoma kinase (ALK). Crizotinib, an orally... 
ALK | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | 2ND-LINE TREATMENT | PHASE-II | EGFR MUTATIONS | IDENTIFICATION | TUMORS | ACTIVATING MUTATIONS | IMMUNOHISTOCHEMISTRY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Microtubule-Associated Proteins - genetics | Humans | Middle Aged | Receptors, Growth Factor - antagonists & inhibitors | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Pyridines - adverse effects | Serine Endopeptidases - genetics | Cell Cycle Proteins - genetics | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Pyridines - administration & dosage | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Receptor Protein-Tyrosine Kinases | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Lung cancer, Small cell | Genetic aspects | Diagnosis | Health aspects | Phosphotransferases | Lymphomas | Pharmaceutical industry | Lung cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 773 - 781
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article